Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label single-arm study of relmacabtagene autoleucel in relapsed/refractory large B-cell lymphoma
CTR20220683Phase 4Completed
- Sponsor
- WuXi AppTec
- Start
- Jan 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 4 trial of relmacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by WuXi AppTec. Started Jan 2023; status: completed.
02
Drugs
relmacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20220683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220683.